{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T20:47:49Z","timestamp":1794689269060,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["332454"],"award-info":[{"award-number":["332454"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["220031"],"award-info":[{"award-number":["220031"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["4709178"],"award-info":[{"award-number":["4709178"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["243595 Pj"],"award-info":[{"award-number":["243595 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-02692"],"award-info":[{"award-number":["2023-02692"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008738","name":"Jeanssons Stiftelser","doi-asserted-by":"publisher","award":["J2023-0094"],"award-info":[{"award-number":["J2023-0094"]}],"id":[{"id":"10.13039\/100008738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70394-3","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:02:21Z","timestamp":1774432941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Solubility based mechanistic profiling of combinatorial drug therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Elham","family":"Gholizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Zangene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uladzislau","family":"Vadadokhau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8603-9754","authenticated-orcid":false,"given":"Danilo","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-1693","authenticated-orcid":false,"given":"Juho J.","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-3352","authenticated-orcid":false,"given":"Rabah","family":"Soliymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-3258","authenticated-orcid":false,"given":"Mathias","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-8773","authenticated-orcid":false,"given":"Esko","family":"Kankuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-8249","authenticated-orcid":false,"given":"Paul A.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8706","authenticated-orcid":false,"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-6328","authenticated-orcid":false,"given":"Amir A.","family":"Saei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6991-8587","authenticated-orcid":false,"given":"Mohieddin","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"70394_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s00108-014-3596-5","volume":"56","author":"K D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, K., Paschka, P. & D\u00f6hner, H. [Acute myeloid leukemia]. Internist 56, 354\u2013363 (2015).","journal-title":"Internist"},{"key":"70394_CR2","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry, E. M. et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 5, 5565\u20135573 (2021).","journal-title":"Blood Adv."},{"key":"70394_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol, S. E. et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 21, 551\u2013560 (2020).","journal-title":"Lancet Oncol."},{"key":"70394_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2643-3230.BCD-23-0067","volume":"5","author":"E Mason-Osann","year":"2024","unstructured":"Mason-Osann, E., Pomeroy, A. E., Palmer, A. C. & Mettetal, J. T. Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood Cancer Discov. 5, 95\u2013105 (2024).","journal-title":"Blood Cancer Discov."},{"key":"70394_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"J Tyner","year":"2018","unstructured":"Tyner, J. et al. Functional genomic landscape of acute myeloid leukemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"70394_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01108-9","volume":"23","author":"K Tang","year":"2021","unstructured":"Tang, K., Schuh, A. C. & Yee, K. W. 3+7 Combined chemotherapy for acute myeloid leukemia:is it time to say goodbye? Curr. Oncol. Rep. 23, 120 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"70394_CR7","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s11864-023-01090-3","volume":"24","author":"J Wang","year":"2023","unstructured":"Wang, J., Tomlinson, B. & Lazarus, H. M. Update on small molecule targeted therapies for acute myeloid leukemia. Curr. Treat. Options Oncol. 24, 770\u2013801 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"70394_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-024-00510-9","volume":"13","author":"M Mirzaie","year":"2024","unstructured":"Mirzaie, M. et al. Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy\/toxicity integration and bipartite network modeling. Oncogenesis 13, 11 (2024).","journal-title":"Oncogenesis"},{"key":"70394_CR9","doi-asserted-by":"publisher","first-page":"118647","DOI":"10.1016\/j.biopha.2025.118647","volume":"192","author":"E Gholizadeh","year":"2025","unstructured":"Gholizadeh, E. et al. Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations. Biomed. Pharmacother. 192, 118647 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"70394_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12953-017-0122-4","volume":"15","author":"A Mateus","year":"2016","unstructured":"Mateus, A., M\u00e4\u00e4tt\u00e4, T. A. & Savitski, M. M. Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes. Proteome Sci. 15, 13 (2016).","journal-title":"Proteome Sci."},{"key":"70394_CR11","doi-asserted-by":"publisher","unstructured":"Zangene, E. et al. DORSSAA: Drug-target interactOmics resource based on stability\/solubility alteration assay. Preprint at https:\/\/doi.org\/10.1101\/2023.12.29.573639 (2023).","DOI":"10.1101\/2023.12.29.573639"},{"key":"70394_CR12","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1021\/acs.jproteome.9b00500","volume":"18","author":"M Gaetani","year":"2019","unstructured":"Gaetani, M. et al. Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution. J. Proteome Res. 18, 4027\u20134037 (2019).","journal-title":"J. Proteome Res."},{"key":"70394_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401502","volume":"11","author":"AA Saei","year":"2024","unstructured":"Saei, A. A. et al. Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification. Adv. Sci. 11, e2401502 (2024).","journal-title":"Adv. Sci."},{"key":"70394_CR14","doi-asserted-by":"crossref","unstructured":"Van Vranken, J. G. et al. Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays. eLife 13, RP95595 (2024).","DOI":"10.7554\/eLife.95595.3"},{"key":"70394_CR15","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/nprot.2015.101","volume":"10","author":"H Franken","year":"2015","unstructured":"Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567\u20131593 (2015).","journal-title":"Nat. Protoc."},{"key":"70394_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255784","volume":"346","author":"MM Savitski","year":"2014","unstructured":"Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).","journal-title":"Science"},{"key":"70394_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189922","volume":"12","author":"M Jafari","year":"2017","unstructured":"Jafari, M., Ansari-Pour, N., Azimzadeh, S. & Mirzaie, M. A logic-based dynamic modeling approach to explicate the evolution of the central dogma of molecular biology. PLoS ONE 12, e0189922 (2017).","journal-title":"PLoS ONE"},{"key":"70394_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","volume":"58","author":"M Tajan","year":"2015","unstructured":"Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T. & Yart, A. SHP2 sails from physiology to pathology. Eur. J. Med. Genet. 58, 509\u2013525 (2015).","journal-title":"Eur. J. Med. Genet."},{"key":"70394_CR19","doi-asserted-by":"publisher","first-page":"188891","DOI":"10.1016\/j.bbcan.2023.188891","volume":"1878","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Ouyang, Y., Li, Z., Wang, X. & Ma, J. S100A8 and S100A9 in cancer. Biochim. Biophys. Acta Rev. Cancer 1878, 188891 (2023).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"70394_CR20","doi-asserted-by":"publisher","first-page":"154235","DOI":"10.1016\/j.prp.2022.154235","volume":"240","author":"C Tian","year":"2022","unstructured":"Tian, C. et al. UCHL1 promotes cancer stemness in triple-negative breast cancer. Pathol. Res. Pract. 240, 154235 (2022).","journal-title":"Pathol. Res. Pract."},{"key":"70394_CR21","doi-asserted-by":"publisher","first-page":"13295","DOI":"10.3390\/ijms241713295","volume":"24","author":"Y Meng","year":"2023","unstructured":"Meng, Y. et al. Research advances in the role of the tropomyosin family in cancer. Int. J. Mol. Sci. 24, 13295 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"70394_CR22","doi-asserted-by":"publisher","first-page":"e33313","DOI":"10.1371\/journal.pone.0033313","volume":"7","author":"A Estecha","year":"2012","unstructured":"Estecha, A., Aguilera-Montilla, N., S\u00e1nchez-Mateos, P. & Puig-Kr\u00f6ger, A. RUNX3 regulates intercellular adhesion molecule 3 (ICAM\u22123) expression during macrophage differentiation and monocyte extravasation. PLoS ONE 7, e33313 (2012).","journal-title":"PLoS ONE"},{"key":"70394_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3563","volume":"13","author":"EK Greuber","year":"2013","unstructured":"Greuber, E. K., Smith-Pearson, P., Wang, J. & Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13, 559\u2013571 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"70394_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter, J. L. et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct. Target. Ther. 5, 288 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"70394_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molcel.2017.06.001","volume":"67","author":"E Bottani","year":"2017","unstructured":"Bottani, E. et al. TTC19 plays a husbandry role on UQCRFS1 turnover in the biogenesis of mitochondrial respiratory complex III. Mol. Cell 67, 96\u2013105 (2017).","journal-title":"Mol. Cell"},{"key":"70394_CR26","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/bmc.3721","volume":"30","author":"RM Borkar","year":"2016","unstructured":"Borkar, R. M. et al. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI\/MS\/MS. Biomed. Chromatogr. 30, 1556\u20131572 (2016).","journal-title":"Biomed. Chromatogr."},{"key":"70394_CR27","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/sj.onc.1207415","volume":"23","author":"S M\u00fcller","year":"2004","unstructured":"M\u00fcller, S., Ledl, A. & Schmidt, D. SUMO: a regulator of gene expression and genome integrity. Oncogene 23, 1998\u20132008 (2004).","journal-title":"Oncogene"},{"key":"70394_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-019-0808-4","volume":"12","author":"A Ghelli Luserna di Ror\u00e0","year":"2019","unstructured":"Ghelli Luserna di Ror\u00e0, A., Martinelli, G. & Simonetti, G. The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window? J. Hematol. Oncol. 12, 123 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"70394_CR29","doi-asserted-by":"publisher","first-page":"584884","DOI":"10.3389\/fonc.2021.584884","volume":"11","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Tumor microenvironmental competitive endogenous RNA network and immune cells act as robust prognostic predictor of acute myeloid leukemia. Front. Oncol. 11, 584884 (2021).","journal-title":"Front. Oncol."},{"key":"70394_CR30","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.3390\/ijms22052470","volume":"22","author":"S Trombetti","year":"2021","unstructured":"Trombetti, S. et al. Oxidative stress and ROS-mediated signaling in leukemia: Novel promising perspectives to eradicate chemoresistant cells in myeloid leukemia. Int. J. Mol. Sci. 22, 2470 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"70394_CR31","doi-asserted-by":"crossref","unstructured":"Addanki, S., Kim, L. E. & Stevens, A. M. Understanding and targeting metabolic vulnerabilities in acute myeloid leukemia: An updated comprehensive review. Cancers17, (2025).","DOI":"10.3390\/cancers17081355"},{"key":"70394_CR32","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","volume":"40","author":"P Saraon","year":"2021","unstructured":"Saraon, P. et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene 40, 4079\u20134093 (2021).","journal-title":"Oncogene"},{"key":"70394_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2021","unstructured":"Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36, 13\u201322 (2021).","journal-title":"Leukemia"},{"key":"70394_CR34","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1038\/sj.onc.1210765","volume":"26","author":"T Pabst","year":"2007","unstructured":"Pabst, T. & Mueller, B. Transcriptional dysregulation during myeloid transformation in AML. Oncogene 26, 6829\u20136837 (2007).","journal-title":"Oncogene"},{"key":"70394_CR35","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.cmet.2024.07.022","volume":"36","author":"S Biffo","year":"2024","unstructured":"Biffo, S., Ruggero, D. & Santoro, M. M. The crosstalk between metabolism and translation. Cell Metab. 36, 1945\u20131962 (2024).","journal-title":"Cell Metab."},{"key":"70394_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.stem.2016.08.003","volume":"19","author":"LA Crews","year":"2016","unstructured":"Crews, L. A. et al. RNA splicing modulation selectively impairs leukemia stem cell maintenance in secondary human AML. Cell Stem Cell 19, 599\u2013612 (2016).","journal-title":"Cell Stem Cell"},{"key":"70394_CR37","doi-asserted-by":"crossref","unstructured":"Chen, C. & Zhang, J. Enhancing leukemia treatment: The role of combined therapies based on amino acid starvation. Cancers16, 1171 (2024).","DOI":"10.3390\/cancers16061171"},{"key":"70394_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the Cancer Dependency Map. Nat. Rev. Cancer 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"70394_CR39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov."},{"key":"70394_CR40","doi-asserted-by":"crossref","unstructured":"Ciciarello, M., Corradi, G., Forte, D., Cavo, M. & Curti, A. Emerging bone marrow microenvironment-driven mechanisms of drug resistance in acute myeloid leukemia: Tangle or chance? Cancers13, 5319 (2021).","DOI":"10.3390\/cancers13215319"},{"key":"70394_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2051-1426-1-13","volume":"1","author":"RM Teague","year":"2013","unstructured":"Teague, R. M. & Kline, J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. Immunother. Cancer 1, 13 (2013).","journal-title":"J. Immunother. Cancer"},{"key":"70394_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6806","volume":"13","author":"C Fan","year":"2024","unstructured":"Fan, C., Yang, X., Yan, L. & Shi, Z. Oxidative stress is two-sided in the treatment of acute myeloid leukemia. Cancer Med. 13, e6806 (2024).","journal-title":"Cancer Med."},{"key":"70394_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev-biochem-072324-031915","volume":"94","author":"LA Yates","year":"2025","unstructured":"Yates, L. A., Zhang, X. & Burgers, P. M. DNA damage and replication stress checkpoints. Annu. Rev. Biochem. 94, 195\u2013221 (2025).","journal-title":"Annu. Rev. Biochem."},{"key":"70394_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41375-019-0552-3","volume":"34","author":"E Weisberg","year":"2020","unstructured":"Weisberg, E. et al. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia 34, 625\u2013629 (2020).","journal-title":"Leukemia"},{"key":"70394_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202400238","volume":"25","author":"P Nickchi","year":"2025","unstructured":"Nickchi, P. et al. Monitoring functional posttranslational modifications using a data-driven proteome informatic pipeline. Proteomics 25, e202400238 (2025).","journal-title":"Proteomics"},{"key":"70394_CR46","doi-asserted-by":"publisher","first-page":"9679","DOI":"10.1073\/pnas.0701806104","volume":"104","author":"X Liu","year":"2007","unstructured":"Liu, X. et al. Sumoylation of nucleophosmin\/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc. Natl. Acad. Sci. USA 104, 9679\u20139684 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70394_CR47","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1128\/MCB.01969-08","volume":"29","author":"J Shandilya","year":"2009","unstructured":"Shandilya, J. et al. Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. Mol. Cell. Biol. 29, 5115\u20135127 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"70394_CR48","first-page":"2766","volume":"62","author":"G Langland","year":"2002","unstructured":"Langland, G. et al. The BLM helicase is necessary for normal DNA double-strand break repair. Cancer Res. 62, 2766\u20132770 (2002).","journal-title":"Cancer Res."},{"key":"70394_CR49","doi-asserted-by":"publisher","first-page":"55301","DOI":"10.1039\/C7RA06666J","volume":"7","author":"Y Wang","year":"2017","unstructured":"Wang, Y. & Luo, J. Acetylation of BLM protein regulates its function in response to DNA damage. RSC Adv. 7, 55301\u201355308 (2017).","journal-title":"RSC Adv."},{"key":"70394_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fgene.2013.00167","volume":"4","author":"KJ Ouyang","year":"2013","unstructured":"Ouyang, K. J., Yagle, M. K., Matunis, M. J. & Ellis, N. A. BLM SUMOylation regulates ssDNA accumulation at stalled replication forks. Front. Genet. 4, 167 (2013).","journal-title":"Front. Genet."},{"key":"70394_CR51","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","volume":"8","author":"AE Pomeroy","year":"2022","unstructured":"Pomeroy, A. E., Schmidt, E. V., Sorger, P. K. & Palmer, A. C. Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer Res. 8, 915\u2013929 (2022).","journal-title":"Trends Cancer Res."},{"key":"70394_CR52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","volume":"1711","author":"L He","year":"2018","unstructured":"He, L. et al. Methods for high-throughput drug combination screening and synergy scoring. Methods Mol. Biol. 1711, 351\u2013398 (2018).","journal-title":"Methods Mol. Biol."},{"key":"70394_CR53","doi-asserted-by":"crossref","unstructured":"Arnone, M. et al. Acute myeloid leukemia stem cells: The challenges of phenotypic heterogeneity. Cancers12, 3742 (2020).","DOI":"10.3390\/cancers12123742"},{"key":"70394_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.leukres.2018.11.015","volume":"76","author":"C Fil\u00ec","year":"2019","unstructured":"Fil\u00ec, C. et al. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. Leuk. Res. 76, 33\u201338 (2019).","journal-title":"Leuk. Res."},{"key":"70394_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/jpm11020117","volume":"11","author":"A Palma","year":"2021","unstructured":"Palma, A. et al. Integrating patient-specific information into logic models of complex diseases: Application to acute myeloid leukemia. J. Pers. Med. 11, 117 (2021).","journal-title":"J. Pers. Med."},{"key":"70394_CR56","doi-asserted-by":"publisher","first-page":"15359","DOI":"10.1021\/ja106896t","volume":"132","author":"JL Price","year":"2010","unstructured":"Price, J. L. et al. Context-dependent effects of asparagine glycosylation on Pin WW folding kinetics and thermodynamics. J. Am. Chem. Soc. 132, 15359\u201315367 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"70394_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","volume":"40","author":"AK Jayavelu","year":"2022","unstructured":"Jayavelu, A. K. et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40, 301\u2013317 (2022).","journal-title":"Cancer Cell"},{"key":"70394_CR58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss, C. I. The toxicity of poisons applied jointly1. Ann. Appl. Biol. 26, 585\u2013615 (1939).","journal-title":"Ann. Appl. Biol."},{"key":"70394_CR59","unstructured":"Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 3, 285\u2013290 (1953)."},{"key":"70394_CR60","doi-asserted-by":"crossref","unstructured":"de Oliveira Lisboa, M., Brofman, P., Schmid-Braz, A. T., Rangel-Pozzo, A. & Mai, S. Chromosomal instability in acute myeloid leukemia. Cancers13, 2655 (2021).","DOI":"10.3390\/cancers13112655"},{"key":"70394_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05647-w","volume":"14","author":"L Guan","year":"2023","unstructured":"Guan, L. et al. Regulation of the tumor immune microenvironment by cancer-derived circular RNAs. Cell Death Dis. 14, 132 (2023).","journal-title":"Cell Death Dis."},{"key":"70394_CR62","doi-asserted-by":"crossref","unstructured":"Chen, Y., Chen, J., Zou, Z., Xu, L. & Li, J. Crosstalk between autophagy and metabolism: implications for cell survival in acute myeloid leukemia. Cell Death Discov. 10, 46 (2024).","DOI":"10.1038\/s41420-024-01823-9"},{"key":"70394_CR63","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1080\/10428194.2021.1907372","volume":"62","author":"J Wallwitz","year":"2021","unstructured":"Wallwitz, J., Aigner, P. & Stoiber, D. Tumor suppressors in acute myeloid leukemia. Leuk. Lymphoma 62, 2320\u20132330 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"70394_CR64","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424\u20132433 (2010).","journal-title":"N. Engl. J. Med."},{"key":"70394_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imr.12246","volume":"263","author":"BA Woods","year":"2015","unstructured":"Woods, B. A. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Immunol. Rev. 263, 22\u201335 (2015).","journal-title":"Immunol. Rev."},{"key":"70394_CR66","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/CCO.0b013e3283313dfa","volume":"21","author":"B Falini","year":"2009","unstructured":"Falini, B., Sportoletti, P. & Martelli, M. P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr. Opin. Oncol. 21, 573\u2013581 (2009).","journal-title":"Curr. Opin. Oncol."},{"key":"70394_CR67","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/gcc.22796","volume":"58","author":"K Barbosa","year":"2019","unstructured":"Barbosa, K., Li, S., Adams, P. D. & Deshpande, A. J. The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes Cancer 58, 875\u2013888 (2019).","journal-title":"Genes Chromosomes Cancer"},{"key":"70394_CR68","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3389\/fonc.2019.00867","volume":"9","author":"S Cuartero","year":"2019","unstructured":"Cuartero, S., Innes, A. J. & Merkenschlager, M. Towards a better understanding of cohesin mutations in AML. Front. Oncol. 9, 867 (2019).","journal-title":"Front. Oncol."},{"key":"70394_CR69","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/leu.2011.66","volume":"25","author":"LS Steelman","year":"2011","unstructured":"Steelman, L. S. et al. Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy. Leukemia 25, 1080\u20131094 (2011).","journal-title":"Leukemia"},{"key":"70394_CR70","doi-asserted-by":"publisher","first-page":"e15701","DOI":"10.14814\/phy2.15701","volume":"11","author":"AB Leuchtmann","year":"2023","unstructured":"Leuchtmann, A. B., Afifi, Y., Ritz, D. & Handschin, C. Effects of high-resistance wheel running on hallmarks of endurance and resistance training adaptations in mice. Physiol. Rep. 11, e15701 (2023).","journal-title":"Physiol. Rep."},{"key":"70394_CR71","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/pmic.201600044","volume":"16","author":"D Pascovici","year":"2016","unstructured":"Pascovici, D., Handler, D. C. L., Wu, J. X. & Haynes, P. A. Multiple testing corrections in quantitative proteomics: A useful but blunt tool. Proteomics 16, 2448\u20132453 (2016).","journal-title":"Proteomics"},{"key":"70394_CR72","doi-asserted-by":"publisher","unstructured":"Saei, A. A. et al. Mapping the GALNT1 substrate landscape with versatile proteomics tools. https:\/\/doi.org\/10.1101\/2022.08.24.505189. (2022)","DOI":"10.1101\/2022.08.24.505189"},{"key":"70394_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21540-6","volume":"12","author":"AA Saei","year":"2021","unstructured":"Saei, A. A. et al. System-wide identification and prioritization of enzyme substrates by thermal analysis. Nat. Commun. 12, 1296 (2021).","journal-title":"Nat. Commun."},{"key":"70394_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26879-4","volume":"12","author":"P Sabatier","year":"2021","unstructured":"Sabatier, P. et al. An integrative proteomics method identifies a regulator of translation during stem cell maintenance and differentiation. Nat. Commun. 12, 6558 (2021).","journal-title":"Nat. Commun."},{"key":"70394_CR75","doi-asserted-by":"publisher","first-page":"D1539","DOI":"10.1093\/nar\/gkac1040","volume":"51","author":"EW Deutsch","year":"2023","unstructured":"Deutsch, E. W. et al. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 51, D1539\u2013D1548 (2023).","journal-title":"Nucleic Acids Res."},{"key":"70394_CR76","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res."},{"key":"70394_CR77","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1074\/mcp.O115.050229","volume":"15","author":"Y Perez-Riverol","year":"2016","unstructured":"Perez-Riverol, Y. et al. PRIDE Inspector toolsuite: moving toward a universal visualization tool for proteomics data standard formats and quality assessment of poteomeXchange datasets. Mol. Cell Proteom. 15, 305\u2013317 (2016).","journal-title":"Mol. Cell Proteom."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70394-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:14:52Z","timestamp":1774433692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70394-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70394"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70394-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7291305\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.H has received research funding from KronosBio, Novartis, Oncopeptides, WNTResearch, and Zentalis Pharmaceuticals, plus personal fees from Amgen and Autolus, unrelated to this work. M.W. is a co-founder and shareholder of MSAID GmbH and a scientific advisor of Momentum Biotechnologies, but he has no operational role in either company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2744"}}